Foghorn Therapeutics Inc.
Biotechnology ResearchView the employees at
Foghorn Therapeutics Inc.-
Katie Benway Research Associate at Foghorn Therapeutics
-
Boston, Massachusetts, United States
-
Rising Star
Danette Daniels VP, Protein Degrader Platform, Foghorn Therapeutics-
Cambridge, Massachusetts, United States
-
Top 5%
Kim Horrigan Associate Director-
Cambridge, Massachusetts, United States
-
Rising Star
Karolina Mizeracka Senior Scientist at Foghorn Therapeutics-
Newton Centre, Massachusetts, United States
-
Top 5%
Allan Reine Chief Financial Officer at Foghorn Therapeutics, Inc-
New York, New York, United States
-
Rising Star
Overview
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.
-